Plozasiran is a small interfering RNA (siRNA, double-stranded oligonucleotide) conjugated with N-acetylgalactosamine to facilitate delivery to and uptake by hepatocytes. In hepatocytes, plozasiran selectively degrades the mRNA for apolipoprotein C3 (APOC3) through the RNA interference mechanism resulting in reduced levels of hepatic and serum APOC3 protein. This, in turn, enhances the activity of lipoprotein lipase and hepatocyte uptake of TG-rich lipoprotein remnants leading to decreases in serum TG.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| REDEMPLO Injection for solution | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| REDEMPLO Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Plozasiran is an active ingredient of these brands:
Lithuania (LT)
United States (US)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.